Inflammation of the glomeruli, microscopic structures that carry out the kidneys' filtering function, results in glomerulonephritis (GN).
According to NIH, In the US, 10% to 15% of end-stage renal disease patients are caused by glomerulonephritis. When prompt attention is not received, the condition typically progresses and eventually results in morbidity. 10% of dialysis patients have chronic glomerulonephritis, making it the third most frequent cause of end-stage renal disease in the US, after hypertension and diabetes mellitus.
Of all end-stage renal disease cases, 25% to 30% have glomerulonephritis; around 25% of patients also have nephritic syndrome.
In countries like the Caribbean, Africa, India, Pakistan, Papua New Guinea, South America, and Malaysia, post-streptococcal glomerulonephritis is still far more common. In Port Harcourt, Nigeria, the incidence of acute glomerulonephritis in children aged 3 to 16 years was 15.5 cases per year, with a male-to-female ratio of 1.1:1; the situation is essentially unchanged today.
Furthermore, according to the NIH, acute nephritis can manifest at any age, even infancy. Children between the ages of 5 and 15 are typically the ones that get post-streptococcal glomerulonephritis. Just 10% of incidents include patients who are 40 years of age or older. Children under the age of six are frequently affected by outbreaks.
A group of diseases known as glomerulonephritis, commonly referred to as nephritis or nephrotic syndrome, affects the glomeruli, the parts of the kidney responsible for filtering blood. A subset of renal illnesses collectively referred to as glomerulonephritis is defined by immune-mediated injury to the mesangium, the capillary endothelium, or the basement membrane, which causes hematuria, proteinuria, and azotemia. An injured kidney makes it unable to eliminate waste products and surplus fluid from the body. Kidney failure could occur if the condition worsens and the kidneys quit functioning entirely. The majority of glomerulonephritis varieties are thought to be progressive illnesses.
Acute glomerulonephritis (GN) forms: Either a main renal cause or a secondary sickness causing renal symptoms is the cause of it.
Chronic glomerulonephritis: It is further classified based on the location of deposits on electron microscopy. Histologically, it is characterized by diffuse thickening of the Glomerulus Basement Membrane (GBM) and endocapillary growth.
The glomerulus is the kidney's filtration organ. There are thousands of glomeruli in each kidney. The glomeruli aid in the body's removal of toxic materials. glomerulonephritis brought on by immune system dysfunction. This condition's precise cause is frequently unknown. Urine loses blood and protein due to damage to the glomeruli. Kidney function is lost in a matter of weeks or months as a result of the fast-developing illness. Glomerulonephritis with rapid progression is the term for this. There are those who have chronic glomerulonephritis but have never had renal illness.
There are several factors that either cause or increase the chance of glomerulonephritis, including:
The diagnostic approach for glomerulonephritis is useful in evaluating the degree of damage as well as the probable cause. The techniques for diagnosis are as follows:
Blood Test
C-reactive protein (CRP), creatinine, immunoglobulins, serum electrolytes, and complete blood count are all measured by blood tests.
Kidney Biopsy
A kidney biopsy is a technique in which a medical practitioner removes one or more microscopic kidney tissue samples and examines the samples under a microscope. When other tests, such as ultrasounds or blood and urine tests, are unable to detect scarring, inflammation (swelling), or protein deposits, this method is utilized to detect them.
Imaging Test
Diagnosis Market Players |
|
Imaging Tests |
Tissue Sampling |
General Electric Company (GE Healthcare) |
Roche Diagnostics |
TECHNOMAC |
Danaher Corporation |
Siemens Healthineers |
Abbott Laboratories |
Med Imaging Solutions |
Hologic, Inc. |
Canon Medical Systems Corporation |
Becton, Dickinson, and Company (BD) |
Gastro diagnostic.Ltd |
Thermo Fisher Scientific, Inc. |
Fujifilm Holdings Corporation (FUJIFILM Medical Systems) |
Genomic Health, Inc. |
Hitachi, Ltd. |
Guardant Health, Inc. |
Toshiba Corporation |
Biocept, Inc. |
Philips Healthcare |
Hipro Biotechnology Co.,Ltd. |
Shimadzu Corporation |
|
Thermo Fisher Scientific |
|
Bristol-Myers Squibb Company |
|
Esaote S.p.A. |
|
Neusoft Medical Systems Co., Ltd. |
|
Mindray Medical International Limited |
|
Genomic Health, Inc. |
|
Agilent Technologies, Inc. |
|
Radiance Imaging system |
Diagnosis Products |
|
Imaging Tests |
Tissue Sampling |
SIGNA™ Architect |
Affirm™ |
Optima™ CT |
Cobas® |
MAGNETOM® |
Aptima™ |
Vereos™ |
Phadia™ |
Discovery™ CT |
Bloodoxy |
SIGNA™ MRI |
Cellient™ |
SIGNA™ Pioneer |
ARCHITECT® |
Revolution™ CT |
Alinity™ |
Discovery™ PET/CT |
BD Vacutainer® |
Gemini™ |
CytoLyt® |
VUE Point™ FX |
ThinPrep® |
Discovery™ MI |
BD SurePath™ |
SOMATOM® |
BD Vacutainer® |
Better2Know |
The cause and symptoms of glomerulonephritis determine how to treat it.
Sometimes the only thing required is to treat the underlying problem, such as by taking medicine to control excessive blood pressure. Antibiotics cure the infection if it is the root cause.
Medicines
Dialysis
Dialysis is used to treat acute renal failure brought on by glomerulonephritis connected to infection. Dialysis makes use of a machine that filters blood and functions similarly to an external, prosthetic kidney. The body accumulates waste materials and fluids to potentially harmful levels. If treatment is not received, this leads to extremely unpleasant symptoms that can potentially be fatal. Before this occurs, dialysis removes undesirable materials and fluids from the blood.
Treatment Market Players |
Treatment Products |
Pfizer Inc. |
Lasix® |
Sandoz Inc. |
Microzide® |
Abbott Laboratories, |
Oretic® |
Teva Pharmaceuticals USA, Inc. |
Hygroton® |
Biogen Inc, |
Thalitone® |
Spiegelberg |
Zymurine |
Johnson & Johnson. |
Azimune |
Merck KGaA |
Azathioprine® |
B. Braun Melsungen AG |
Azoran® |
Terumo Corporation |
Cyclosporine® |
Microvention Inc. |
Neoral® |
Camber Pharmaceuticals, Inc. |
Soliris® |
Upsher-Smith Laboratories, LLC, |
Myfortic® |
Bristol-Myers Squibb Company |
CellCept® |
GlaxoSmithKline Plc |
Capoten® |
Zydus Cadila Healthcare Ltd. |
Lotensin® |
In October 2023 TGA approved Benzylpenicillin benzathine 1.2 million I.U powder and solvent for suspension for injection of Brancaster Pharma, UK for the treatment of acute Glomerulonephritis.
The DiseaseLandscape Insights consultancy firm provides valuable support in future market trends on the development of new pharmaceutical products. This support helps to streamline the planning and execution of clinical trials of novel medications and treatments, implement effective patient recruitment strategies, ensure regulatory compliance, and increase the likelihood of successful trial outcomes.
Phase 1 |
Phase 2 |
Phase 3 |
Phase 4 |
Study of HRS-5965 in Healthy Subjects and Subjects with Renal Insufficiency |
Daratumumab for Treatment of Proliferative Glomerulonephritis with Monoclonal Immune Deposits |
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis |
Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis |
Study of ARO-C3 in Adult Healthy Volunteers and Patients with Complement Mediated Renal Disease |
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy |
Clinical Study of Rituximab for the Treatment of Idiopathic Membranous Nephropathy with Nephrotic Syndrome |
Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis |
A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of HS-10390 in Healthy Subjects |
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN |
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN |
Effectiveness of Mycophenolate Mofetil Combined with Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus |
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy |
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) |
A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants with Primary Membranous Nephropathy |
MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN |
A Clinical Study of MIL62 in Primary Membranous Nephropathy |
A Study to Investigate Safety and Effect of Sparsentan in Combination with SGLT2 Inhibition in Participants with IgAN |
A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants with Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression |
Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis |
DiseaseLandscape Insights (DLI) assists manufacturers in developing and implementing viable remedies to interrupt and manage the glomerulonephritis epidemic. Furthermore, there is an increasing need for diagnostic tools, and clinical evaluations, because of greater awareness and estimated epidemics.
DiseaseLandscape Insights offers essential knowledge and expertise to major stakeholders involved in the manufacture of therapeutic goods. DLI support makes it easier for market participants to organize and carry out clinical trials for innovative medicines and pharmaceuticals, patient recruiting tactics, and regulatory compliance. By understanding disease patterns, treatment needs, and technological advancements, companies tailor their products and services to meet evolving demands and foster business expansion and success.
How we can help?